

Haematologica
HAEMATOL/2017/178996
Version 3

GA101 P329G LALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B cell depletion and antitumor activity

Sylvia Herter, Frank Herting, Gunter Muth, Erwin van Puijenbroek, Tilman Schlothauer, Claudia Ferrara, Kevin Brady, Sabine Lang, Marina Bacac, Ekkehard Mössner, Pablo Umana, and Christian Klein

Disclosures: All authors are or were employees of Roche at the time when the studies were performed

Contributions: SH, FH, GM, EvP, TS, CF, KB, SL performed research and data analysis, SH, FH, TS, SL, MB, EM, PU, CK planned, oversaw and designed research, all authors participated in writing and reviewing the manuscript